• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

‘Cash-Rich’ Samsung Biologics and SK Bioscience Accelerate Investments Amid Biotech Industry Downturn

김나영 기자

steaming@fntimes.com

기사입력 : 2025-05-07 09:40 최종수정 : 2025-05-07 09:49

◇ Samsung Biologics and SK Bioscience Hold Over KRW 1 Trillion in Cash Assets Despite Industry-Wide Funding Crunch
◇ Bold M&As and Facility Investments Signal Confidence in Securing Future Growth Engines

Comparison of Cash and Cash Equivalents and Borrowings of Samsung Biologics and SK Bioscience in 2024 (Consolidated Basis)

Comparison of Cash and Cash Equivalents and Borrowings of Samsung Biologics and SK Bioscience in 2024 (Consolidated Basis)

이미지 확대보기
[Korea Financial Times, Kim Nayoung] Samsung Biologics and SK Bioscience, leading contract development and manufacturing organizations (CDMOs) in South Korea’s biotech sector, are continuing bold investment strategies backed by solid financial health. Both companies surpassed KRW 1 trillion in cash and cash equivalents last year, bucking the tightening capital conditions affecting the broader biotech industry.

◇ Samsung Biologics Surpasses KRW 1 Trillion in Cash Assets

According to a Financial Supervisory Service disclosure on May 6, 2025, Samsung Biologics held KRW 1.2986 trillion in total cash and cash equivalents at the end of last year, comprising KRW 391.2 billion in cash and cash equivalents and KRW 907.3 billion in short-term financial instruments.

This represents a decrease of about KRW 700 billion from the previous year, when the company held KRW 2.018 trillion in cash assets (KRW 367.9 billion in cash and KRW 1.65 trillion in short-term financial products). The reduction reflects efforts to improve the company’s financial structure. Samsung Biologics repaid approximately KRW 800 billion in borrowings and bonds in 2024, lowering its debt ratio to 59%.

Despite a smaller cash reserve, investment appetite increased. The company spent KRW 2.0012 trillion on facility investments, including CDMO plants, a 155.8% increase from KRW 782.2 billion in 2023.

Last month, Samsung Biologics began full-scale operations of its 180,000-liter Plant 5, raising total production capacity to 784,000 liters-the largest globally. The company plans to invest a total of KRW 7.5 trillion by 2032 to build its second Bio Campus (Plants 5–8), expanding capacity to 1.324 million liters. Internal discussions are also underway to establish dedicated production facilities for new modalities such as antibody-drug conjugates (ADC).

Strong cash flow underpins this investment drive. Samsung Biologics generated KRW 1.9604 trillion in cash from operating activities in 2024. While borrowings and bonds totaled KRW 1.3398 trillion, resulting in net debt of KRW 41.2 billion, operating cash flow comfortably covers liabilities.

This contrasts sharply with the domestic biotech sector’s funding squeeze. Venture capital data from The VC shows that investment deals in Korea’s bio, medical, and healthcare sectors dropped from 522 in 2021 to 225 last year, with investment amounts shrinking from KRW 3.7358 trillion to KRW 1.0934 trillion.

An industry insider commented, “Unlike other biotech firms, Samsung Biologics has a stable revenue base and cash flow. It is one of the rare companies that can withstand increased depreciation expenses from expanded facility investments such as Plant 5.”

◇ SK Bioscience Tops in Net Cash, Ready for M&A Expansion

SK Bioscience also boasts a strong cash position, with KRW 1.1581 trillion in cash and cash equivalents last year, up 11.1% from KRW 1.2741 trillion at the end of 2023.

Notably, SK Bioscience’s net cash position is KRW 774.8 billion after deducting total borrowings of KRW 383.3 billion.

While Samsung Biologics leads in cash assets among KOSPI-listed biotech firms, SK Bioscience ranks first in net cash. The company accumulated substantial cash during the COVID-19 pandemic, generating billions in operating profit centered on its vaccine business. It also raised KRW 1.5 trillion through an initial public offering (IPO) in 2021.

With ample financial resources, SK Bioscience is actively pursuing business diversification and future growth through mergers and acquisitions (M&A).

SK Bioscience acquired the German CDMO company IDT Biologika for KRW 356.4 billion in June last year. In October, it purchased a controlling stake in U.S. biotech company PinA BioSolutions for KRW 4.1 billion. The company is also moving quickly to secure next-generation technologies, including a conditional acquisition of U.S.-based Sunflower’s shares.

SK Bioscience plans to continue investing in promising global biotech companies.

A company spokesperson stated, “We will secure competitiveness through investments and M&A in promising companies with excellent technologies, laying the foundation for a full-scale leap as a global company.”

Kim Nayoung, Korea Finacial Times (steaming@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

기자의 기사 더보기 전체보기

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 Hanwha Solutions’ Pretax Profit Owes to Asset Sale, Not Core Business Hanwha Solutions’ third-quarter pretax profit turned positive, but the driver was not its core business. It was a single asset sale. The company sold intangible assets with a book value of KRW 12.5 billion and booked a gain of KRW 199.7 billion. Without that gain, this year’s third quarter would show a pretax loss of KRW 176.3 billion.The proceeds from the disposal differ by only KRW 0.8 billion from the amount of fixed assets Hanwha Solutions sold to TransGrid Energy, a Hanwha Group affiliate, over the same period. TransGrid Energy is a subsidiary of a joint venture in which Hanwha Solution 2 Lotte Chemical Pays Down JV Debt With KRW 600 Billion as Its Own Loans Get a Three-Year Reprieve Lotte Chemical contributed KRW 600 billion to help its joint venture H&L Advanced repay existing borrowings. But it has also taken on an impairment loss on its JV shares and faces additional funding support obligations. The value of the shares recognized in the merger-date accounting was less than half the per-share value assessed by an external valuation firm when the merger ratio was set. While pouring large sums into improving the JV’s finances, Lotte Chemical itself has agreed with its creditors to a three-year deferral of repayment on its covenant debt.According to the Financial Supe 3 S-Oil Hits Record Profit, but Shares Sink 40% as Shaheen Bet Looms S-Oil posted record quarterly operating profit in the third quarter of this year, yet its share price has fallen about 40% from its peak.Despite strong results in refining and lubricants, earnings are expected to decline next year. The company also faces the task of proving the profitability of the petrochemical project Shaheen, in which it has invested more than KRW 9 trillion, amid concerns over oversupply.S-Oil reported third-quarter revenue of KRW 11.9687 trillion and operating profit of KRW 1.4067 trillion. Operating profit surged 514% from a year earlier and beat the market consensus by
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[카드뉴스] 성북동 언덕길, 만해의 집을 만나다
[카드뉴스] 약재 향 따라 걷는 서울약령시
[그래픽 뉴스] ‘순대’가 경제용어라고? 순(純)대외자산, 한국의 진짜 해외자산은 얼마일까?
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'

FT도서

더보기